Morepen Labs Board Approves Q1 FY27 Results, Sets Record Date for Dividend, Reappoints CMD
Morepen Laboratories announced Q1 FY27 results with consolidated revenue at ₹570.13 crore. The board approved the dividend record date as September 19, 2026. Mr. Sushil Suri was re-appointed as Chairman & Managing Director for three years from October 20, 2026. The 41st AGM is on September 26, 2026.
The approval of financial results, dividend record date, and re-appointment of a key management person are material events for shareholders and stakeholders, impacting governance and future strategy.
The announcement includes routine financial results, dividend declaration, and management re-appointment, which are standard corporate actions. While the re-appointment is positive for stability, the overall impact is neutral as it doesn't signal significant new growth or distress.
Morepen Laboratories Limited's Board of Directors, in a meeting held on August 4, 2026, approved the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also set Saturday, September 19, 2026, as the record date for determining eligible members for the final dividend for the financial year ended March 31, 2026, subject to member approval at the upcoming 41st Annual General Meeting (AGM).
Furthermore, the board approved the extension of the timeline for hiving off the Medical Devices Business into its subsidiary, Morepen Medipath Limited, on a slump sale basis, pending member approval at the 41st AGM. In a significant management decision, the board approved the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director for a further period of three years, effective from October 20, 2026, to October 19, 2029, subject to shareholder approval at the 41st AGM. Mr. Suri, a Chartered Accountant with over 30 years of experience in the pharmaceuticals industry, is the brother of Mr. Sanjay Suri, a promoter and Managing Director of the company.
The 41st AGM is scheduled to be held on Saturday, September 26, 2026, via video conferencing. The financial results indicate a revenue from operations of ₹570.13 crore for the consolidated entity and ₹541.04 crore for the standalone entity for the quarter ended June 30, 2026.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.